TF and metastatic prostate carcinoma: This modality has been successfully applied to destruct ERG, a TF overexpressed in 50% of both primary and metastatic prostate cancer [102], and LEF1, another cancer-related TF involved in migration and invasion, with potent efficacy in cultured cells.